ATE452643T1 - Herstellung eines biologischen faktors und schaffung einer immunologisch vorteilhaften umgebung unter verwendung genetisch veränderter sertolizellen - Google Patents

Herstellung eines biologischen faktors und schaffung einer immunologisch vorteilhaften umgebung unter verwendung genetisch veränderter sertolizellen

Info

Publication number
ATE452643T1
ATE452643T1 AT99961585T AT99961585T ATE452643T1 AT E452643 T1 ATE452643 T1 AT E452643T1 AT 99961585 T AT99961585 T AT 99961585T AT 99961585 T AT99961585 T AT 99961585T AT E452643 T1 ATE452643 T1 AT E452643T1
Authority
AT
Austria
Prior art keywords
biological factor
sertoli cells
producing
cells
sertolic
Prior art date
Application number
AT99961585T
Other languages
English (en)
Inventor
A Kirkpatrick Shaun
Paul Gores
Craig Halberstadt
Original Assignee
Sertoli Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sertoli Technologies Inc filed Critical Sertoli Technologies Inc
Application granted granted Critical
Publication of ATE452643T1 publication Critical patent/ATE452643T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/52—Sperm; Prostate; Seminal fluid; Leydig cells of testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT99961585T 1998-11-06 1999-11-04 Herstellung eines biologischen faktors und schaffung einer immunologisch vorteilhaften umgebung unter verwendung genetisch veränderter sertolizellen ATE452643T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10743898P 1998-11-06 1998-11-06
PCT/US1999/026072 WO2000027409A1 (en) 1998-11-06 1999-11-04 Production of a biological factor and creation of an immunologically privileged environment using genetically altered sertoli cells

Publications (1)

Publication Number Publication Date
ATE452643T1 true ATE452643T1 (de) 2010-01-15

Family

ID=22316637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99961585T ATE452643T1 (de) 1998-11-06 1999-11-04 Herstellung eines biologischen faktors und schaffung einer immunologisch vorteilhaften umgebung unter verwendung genetisch veränderter sertolizellen

Country Status (10)

Country Link
EP (1) EP1126858B1 (de)
JP (1) JP5323293B2 (de)
AT (1) ATE452643T1 (de)
AU (1) AU767763B2 (de)
CA (1) CA2349475C (de)
DE (1) DE69941849D1 (de)
DK (1) DK1126858T3 (de)
ES (1) ES2338076T3 (de)
NO (1) NO20012214L (de)
WO (1) WO2000027409A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
DE60128130T2 (de) * 2000-11-03 2007-12-27 Zymogenetics, Inc., Seattle Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a
AU2007278850B2 (en) * 2006-07-28 2013-06-06 Sertocell Biotechnology (Us) Corp. Adult sertoli cells and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725854A (en) * 1994-04-13 1998-03-10 Research Corporation Technologies, Inc. Methods of treating disease using sertoli cells an allografts or xenografts
US5702700A (en) * 1995-03-13 1997-12-30 University Of South Florida Sertoli cells as neurorecovery inducing cells for Parkinson's disease

Also Published As

Publication number Publication date
ES2338076T3 (es) 2010-05-03
AU1813200A (en) 2000-05-29
NO20012214L (no) 2001-07-06
JP2002529419A (ja) 2002-09-10
CA2349475A1 (en) 2000-05-18
AU767763B2 (en) 2003-11-20
DE69941849D1 (de) 2010-02-04
EP1126858B1 (de) 2009-12-23
CA2349475C (en) 2010-01-05
NO20012214D0 (no) 2001-05-04
DK1126858T3 (da) 2010-03-01
JP5323293B2 (ja) 2013-10-23
WO2000027409A1 (en) 2000-05-18
EP1126858A4 (de) 2004-06-30
EP1126858A1 (de) 2001-08-29

Similar Documents

Publication Publication Date Title
BR0316468A (pt) Composição para reparar tecido orgânico e métodos para preparar tecido orgânico, uma imperfeição de tecido orgânico e um ferimento de queimadura em um paciente e para produzir uma composição para preparar tecido orgânico
AR012399A1 (es) Una region regulatoria de 5' de oleosiina para la modificacion de composicion lipida de semilla de planta
DE69536014D1 (de) Verfahren zur herstellung angereicherter hämatopoietischer zusammensetzungen, dadurch hergestellte zusammensetzungen sowie deren verwendungen
ATE297726T1 (de) Forskolin zur entwicklung magerer körpermasse
DE69525151D1 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
ATE12255T1 (de) Verfahren zur herstellung von selbstreproduzierenden pankreatischen inseln aehnlichen strukturen von saeugetieren.
ES2119250T3 (es) Composiciones y metodos para estimular el crecimiento y diferenciacion de megacariocitos.
DE69331550D1 (de) Klonierung und expression von biologisch aktiver alpha-galaktosidase a
ATE193729T1 (de) Geminivirus-basiertes-genexpressionsystem
BR0311362A (pt) métodos, composições e fatores de crescimento e de diferenciação para produzir células produtoras de insulina
ATE196507T1 (de) Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
KR850007275A (ko) 기능성 인체인자 ⅷ의 제조방법
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
BR9710689A (pt) Processo para tratar diarr-ia aguda e para proporcionar terapia a um mam¡fero tendo diarr-ia e prepara-Æo terap-utica para redu-Æo de sintomas de diarr-ia
DE69737023D1 (de) Methode zur behandlung von krebs und pathogenen infektionen unter verwendung von antigen-präsentierenden zellen beladen mit rna
CA2244659A1 (en) Biological reactor for the cultivation of cells
ATE377076T1 (de) Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen
AR020735A1 (es) Un procedimiento para la obtencion de un polipeptido glucosilado a partir de celulas eucarioticas
ATE169919T1 (de) Isolierung und struktur von spongistatin 5, 7, 8 und 9 und deren verwendung als antitumor-mittel
ATE299187T1 (de) Modifizierter humaner granulozyten-kolonie stimulierenderfaktor sowie verfahren zur herstellung desselben
ATE330003T1 (de) Rekombinanter stabiler zellklon, seine herstellung und verwendung
DE69637709D1 (de) Durch elektroporation vermittelter molekulartransfer in intakten pflanzen
DE69109298D1 (de) Verfahren zur modifizierung von zell-, gewebe- oder wirts-tropismus eines mikroorganismus, so erhaltene rekombinante mikroorganismen sowie deren verwendung in medizin und tiermedizin.
BR9707994A (pt) Adenovírus recombinantes defectivo composição farmacêutica utilização do adenovirus composição e processo de preparação de células t citotóxicas especificas de um antigene tumoral
ATE452643T1 (de) Herstellung eines biologischen faktors und schaffung einer immunologisch vorteilhaften umgebung unter verwendung genetisch veränderter sertolizellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties